BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11996482)

  • 1. Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
    Benchalal M; Yahchouchy-Chouillard E; Fouere S; Fingerhut A
    Ann Oncol; 2002 Mar; 13(3):480-1. PubMed ID: 11996482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylactic reaction associated with intravenous administration of folinic acid in a patient with colon cancer.
    Katirtzoglou NA; Hotchkiss S; Gambaccini M; Kaley K; Syrigos KN; Saif MW
    In Vivo; 2011; 25(6):995-6. PubMed ID: 22021695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
    Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W
    Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
    Bouzid K; Khalfallah S; Tujakowski J; Piko B; Purkalne G; Plate S; Padrik P; Serafy M; Pshevloutsky EM; Boussard B;
    Ann Oncol; 2003 Jul; 14(7):1106-14. PubMed ID: 12853354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
    Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
    Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
    Kamoshita N; Makita F; Kobayashi M; Matsuzaki Y; Kabeya K
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):397-401. PubMed ID: 17353631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
    Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
    J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
    Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
    J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases--a pilot experience.
    Melichar B; Dvorák J; Jandík P; Tousková M; Malírová E; Megancová J; Voboril Z
    Hepatogastroenterology; 2001; 48(42):1721-6. PubMed ID: 11813608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
    Ychou M; Hohenberger W; Thezenas S; Navarro M; Maurel J; Bokemeyer C; Shacham-Shmueli E; Rivera F; Kwok-Keung Choi C; Santoro A
    Ann Oncol; 2009 Dec; 20(12):1964-70. PubMed ID: 19567451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
    Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
    Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
    Reddy GK
    Clin Colorectal Cancer; 2004 Nov; 4(4):230-2. PubMed ID: 15555203
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
    Moehler M; Hoffmann T; Zanke C; Hohl H; Burg H; Ehscheid P; Schwindt P; Adami B; Schroeder M; Klein O; Baldus M; Galle PR; Heike M
    Anticancer Drugs; 2003 Jan; 14(1):79-85. PubMed ID: 12544262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anaphylactic reaction to oxaliplatin--a case of colon cancer].
    Sagawa T; Sato Y; Abe S; Okuda T; Araki N; Takahari D; Okamoto T; Takayama T; Kato J; Niitsu Y
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2093-6. PubMed ID: 17197761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
    Graeven U; Ridwelski K; Artandi M; Espana P; Schölmerich J; Rosales AM; Carlsson G; Borner M; Boussard B; Schmiegel W
    Oncol Rep; 2005 Apr; 13(4):681-8. PubMed ID: 15756442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progression of adjuvant chemotherapy for colon cancer].
    He YJ; Dong QM; Li YH
    Ai Zheng; 2005 Dec; 24(12):1546-9. PubMed ID: 16351811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.